© Reuters. Moderna logo and stock graph are seen displayed in this illustration taken, May 3, 2022. REUTERS/Dado Ruvic/Illustration
US500
-0.53%
Add to/Remove from Watchlist
Add to Watchlist
Add Position
Position added successfully to:
Please name your holdings portfolio
Type:
BUY
SELL
Date:
Amount:
Price
Point Value:
Leverage:
1:1
1:10
1:25
1:50
1:100
1:200
1:400
1:500
1:1000
Commission:
Create New Watchlist
Create
Create a new holdings portfolio
Add
Create
+ Add another position
Close
MRNA
+13.12%
Add to/Remove from Watchlist
Add to Watchlist
Add Position
Position added successfully to:
Please name your holdings portfolio
Type:
BUY
SELL
Date:
Amount:
Price
Point Value:
Leverage:
1:1
1:10
1:25
1:50
1:100
1:200
1:400
1:500
1:1000
Commission:
Create New Watchlist
Create
Create a new holdings portfolio
Add
Create
+ Add another position
Close
(Reuters) -Moderna shares gained nearly 14% on Tuesday as brokerage Oppenheimer upgraded the stock to “outperform” and the vaccine maker’s CEO reiterated the company’s goal of achieving sales growth in 2025.
Shares of the company slumped nearly 45% in 2023, marking their worst annual performance to date, weighed down by weak sales of its COVID-19 vaccine.
“With the expected launch of our RSV (respiratory syncytial virus) vaccine candidate in 2024 and potential launch of our flu/COVID combination vaccine as early as 2025, we believe Moderna (NASDAQ:MRNA) will experience sales growth in 2025,” CEO Stéphane Bancel said in a letter to shareholders.
According to Oppenheimer, Moderna could have five products on the market by 2026.
Moderna shares fell 29% in 2022 after they more than doubled in 2021. The stock had tracked a fivefold increase in 2020.
The stock was among the biggest gainers on the S&P 500 Healthcare index on Tuesday.
Bancel reiterated the company’s goal to break even in 2026 as revenue grows and research and development costs for late-stage candidates recede.
Moderna had previously said it expects $4 billion in revenue in 2024 from the sale of its COVID and RSV vaccines.
Bancel recently took over the responsibility to oversee sales and marketing of vaccine after Arpa Garay stepped down as the chief commercial officer.
Moderna had said in November it would only hit the low end of its sales forecast of $6 billion to $8 billion for 2023, reflecting weaker demand for COVID vaccines.
Moderna’s price to tangible book value ratio, a common benchmark for valuing stocks, stood at 2.84 compared with 1.21 for rival BioNtech.
Source: Investing.com
